CAS: 14001-66-2; 5-Bromo-2-Methoxypyrimidine

相似化合物

17758-11-1 121487-12-5 214290-49-0

上下游产品

methanol 5-bromo-2-methylthiopyrimidine 2,5-dibromopyrimidine 5-Bromo-2-chloropyrimidine (E)-methyl 3-(2-methoxy-5-pyrimidinyl)acrylate (5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol 2-methoxy-5-vinylpyrimidine (2-methoxypyrimidin-5-yl)boronic acid

5-溴-2-甲巯基嘧啶置于甲醇,Chloroamine-T体系中,用 溶剂黄146 用作溶剂,化学反应 2.0H,以72%的收率获得5-溴-2-甲氧基嘧啶
参考文献:Sandosham,Jessie; Benneche,Tore; Moeller,Bjoerg,Acta Chemica Scandinavica. Series B: Organic Chemistry And Biochemistry,1988,Vol. 42,# 7,P. 455-461
标题:Sandosham,Jessie; Benneche,Tore; Moeller,Bjoerg,Acta Chemica Scandinavica. Series B: Organic Chemistry And Biochemistry,1988,Vol. 42,# 7,P. 455-461

专利信息

专利号:US-8404670-B2
优先权日:2009-02-11
标题:Histamine H3 inverse agonists and antagonists and methods of use thereof
发明人：CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.